IP Library Granted Patent US 10,363,311
Granted Patent B2
US 10,363,311 · App. 14/472,779 · Granted Jul 30, 2019

Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

Inventors: George Georgiou (Austin, TX); Everett Stone (Austin, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
A61K45/06A61K38/51C12N9/88C12Y404/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,363,311
App. No.
14/472,779
Granted
Jul 30, 2019
Kind
B2
Abstract

Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.

Claims (12)

1. An isolated, modified primate cystathionine-γ-lyase (CGL) enzyme having at least one substitution relative to a native primate CGL amino acid sequence (see SEQ ID NOs: 1 and 7-10), said at least one substitution including a threonine at position 59 of the native primate CGL sequence.

2. The enzyme of claim 1 , further comprising a valine substitution at position 339.

3. The enzyme of claim 1 , further comprising a heterologous peptide segment.

4. The enzyme of claim 3 , wherein the heterologous peptide segment is an XTEN peptide, an IgG Fc, an albumin, or an albumin binding peptide.

5. The enzyme of claim 1 , wherein the enzyme is coupled to polyethylene glycol (PEG).

6. The enzyme of claim 5 , wherein the enzyme is coupled to PEG via one or more lysine or cystine residues.

7. An isolated, modified primate cystathionine-γ-lyase (CGL) enzyme having at least two substitutions relative to a native primate CGL amino acid sequence (see SEQ ID NOs: 1 and 7-10), said at least two substitutions including a threonine at position 59 and a valine at position 339 of the native primate CGL sequence.

8. A nucleic acid comprising a nucleotide sequence encoding the enzyme of claim 1 .

9. The nucleic acid of claim 8 , wherein the nucleic acid is codon optimized for expression in bacteria, fungus, insects, or mammals.

10. An expression vector comprising the nucleic acid of claim 8 .

11. A host cell comprising the nucleic acid of claim 8 .

12. The host cell of claim 11 , wherein the host cell is a bacterial cell, a fungal cell, an insect cell, or a mammalian cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 25, 2015
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035089/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2014
From: GEORGIOU, GEORGE; STONE, EVERETT
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 033837/0806 →
Continuity (3)
Provisional Application 61871727 · Aug 29, 2013
Provisional Application 61948106 · Mar 5, 2014
Related Publication 20150064160A1 · Mar 5, 2015